QIA Stock Chart & Stats
€35.35
€0.28(0.64%)
At close: 4:00 PM EST
€35.35
€0.28(0.64%)
Day’s Range― - ―
52-Week Range€27.56 - €47.60
Previous CloseN/A
Volume22.54K
Average Volume (3M)745.03K
Market Cap
€7.22B
Enterprise Value€8.54B
Total Cash (Recent Filing)€646.29M
Total Debt (Recent Filing)€1.65B
Price to Earnings (P/E)21.2
Beta0.37
Next Earnings
Jul 23, 2026EPS Estimate
0.53Next Dividend Ex-DateN/A
Dividend Yield3.37%
Share Statistics
EPS (TTM)1.89
Shares Outstanding206,074,750
10 Day Avg. Volume777,009
30 Day Avg. Volume745,035
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.61
Price to Sales (P/S)4.71
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€35.74Price Target Upside1.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)2.13
Revenue Forecast (FY)€1.89B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables / Installed BaseQiagen’s business model centers on consumables and instrument placements that create repeat purchasing and durable revenue. An installed base of instruments supports long-term pull-through of proprietary kits and reagents, underpinning predictable recurring revenue and high lifetime customer value.
Revenue Acceleration And Strong MarginsSizable TTM revenue acceleration paired with sustained gross and operating margins signals improving core demand and operational leverage. Durable margin structure (~62% gross, ~25% EBIT) provides a buffer to absorb cyclical headwinds and funds reinvestment into assays, platforms, and digital offerings over the medium term.
Solid Cash GenerationConsistent positive operating and free cash flow, with OCF exceeding net income, demonstrates quality earnings conversion and internal funding capacity. This cash generation supports capital allocation for R&D, tuck-in M&A, and dividend/credit obligations without sole reliance on external financing.
Bears Say
QuantiFERON Demand ExposureSignificant exposure to QuantiFERON and immigration testing makes revenue sensitive to regulatory and policy-driven volume shifts. A structural decline in immigration testing or slower recovery limits a major revenue stream, requiring successful product diversification and ramp of other pillars to sustain medium-term growth.
Historic Margin VolatilityPast sharp margin troughs indicate that earnings are subject to cyclical and product-mix swings. Persistent volatility complicates forecasting and capital allocation; lasting improvement depends on stable demand across core assays and sustained operating discipline to prevent returns slipping during downturns.
Leverage And Equity DeclineAlthough leverage has improved, a meaningful debt load and declining equity reduce financial flexibility if revenues soften. This structural constraint limits aggressive capital spending or large acquisitions without raising leverage or diluting equity, posing a risk during prolonged industry headwinds.
Qiagen News
QIA FAQ
What was Qiagen’s price range in the past 12 months?
Qiagen lowest stock price was €27.56 and its highest was €47.59 in the past 12 months.
What is Qiagen’s market cap?
Qiagen’s market cap is €7.22B.
When is Qiagen’s upcoming earnings report date?
Qiagen’s upcoming earnings report date is Jul 23, 2026 which is in 20 days.
How were Qiagen’s earnings last quarter?
Qiagen released its earnings results on May 06, 2026. The company reported €0.472 earnings per share for the quarter, missing the consensus estimate of €0.474 by -€0.002.
Is Qiagen overvalued?
According to Wall Street analysts Qiagen’s price is currently Undervalued.
Does Qiagen pay dividends?
Qiagen pays a Semiannually dividend of €0.306 which represents an annual dividend yield of 3.37%. See more information on Qiagen dividends here
What is Qiagen’s EPS estimate?
Qiagen’s EPS estimate is 0.53.
How many shares outstanding does Qiagen have?
Qiagen has 206,074,750 shares outstanding.
What happened to Qiagen’s price movement after its last earnings report?
Qiagen reported an EPS of €0.472 in its last earnings report, missing expectations of €0.474. Following the earnings report the stock price went down -2.565%.
Which hedge fund is a major shareholder of Qiagen?
Currently, no hedge funds are holding shares in DE:QIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qiagen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€35.74 (1.10% Upside)
€35.74 (1.10% Upside)
Blogger Sentiment
Bullish
DE:QIA Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €2.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.54%
12-Months-Change
Fundamentals
Return on Equity
11.28%
Trailing 12-Months
Asset Growth
4.27%
Trailing 12-Months
Company Description
Qiagen
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
QIA Company Deck
QIA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: QIAGEN beat Q4 and full-year outlooks, delivered margin expansion and strong free cash flow, progressed multiple growth pillars (Sample Technologies, QuantiFERON, QIAstat, QIAcuity, QDI), completed strategic acquisitions (Parse, Genoox) and set 2026 guidance for continued profitable growth. Notable near-term challenges include declines in PCR/NGS consumables, regional softness (U.S. and China), tariff and FX headwinds, and short-term dilution from Parse and discontinued product lines that weigh on Q1/first-half 2026. Management expects improvement and acceleration into H2 2026 driven by new product launches and strengthened growth pillars.View all DE:QIA earnings summariesQIA Stock 12 Month Forecast
Average Price Target
€35.74
▲(1.10% Upside)
Technical Analysis
Options Prices
Currently, No data available
---